Artículo

Engineering tumor hypersusceptibility to checkpoint immunotherapy

Fernandez, ArielIcon
Fecha de publicación: 04/09/2017
Editorial: Cell Press
Revista: Trends in Cancer
ISSN: 2405-8033
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:

Resumen

The immune checkpoint blockerpembrolizumab(Keytruda)hasproven successful in treating solidtumors harboring a DNA mismatchrepair (MMR) deficiency. We showthat it is possible to generate adrug-promoted phenotype mim-icking the MMR deficiency in solidtumors, and thereby to engineer ageneric hypersusceptibility to Key-truda through drug-induced meta-bolic stress on DNA synthesis. Thepotential of such drug–Keytrudacombinations as universal treat-ments for solid tumors deserves clinical evaluation.
Palabras clave: CHECKPOINT BLOCKADE , DNA MISMATCH REPAIR , EPIGENETIC CANCER THERAPY , IMMUNOTHERAPY , PHOSPHOINOSITIDE 3-KINASE , SOLID TUMOR
 
Archivos asociados
Thumbnail
 
Tamaño: 509.0Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/85814
URL: https://www.cell.com/trends/cancer/fulltext/S2405-8033(17)30159-0
DOI: http://dx.doi.org/10.1016/j.trecan.2017.08.002
Colecciones
Articulos(INQUISUR)
Articulos de INST.DE QUIMICA DEL SUR
Citación
Fernandez, Ariel; Engineering tumor hypersusceptibility to checkpoint immunotherapy; Cell Press; Trends in Cancer; 3; 10; 4-9-2017; 675-677
Compartir
Altmétricas